FDA Commissioner Suggests There Is No Reason For A DEA Delay On Rescheduling
“There is no reason for the DEA to delay”
He stressed that he believes Congress should be the first to act on rescheduling.
On April 11, the U.S. Food and Drug Administration Commissioner Robert Califf testified to the House of Representatives Committee on Oversight and Accountability, causing many in the industry to speculate when and if the Drug and Enforcement Administration (DEA) will change the scheduling for cannabis. The most critical statement in his testimony came when being questioned by Congresswoman Nancy Mace. She wanted to know when the DEA would act and Califf responded that he didn’t know.
However, when she pushed for an answer and asked whether it would be this year, Califf responded: “There is no reason for the DEA to delay.”
Still, he cautioned that the DEA needed to take into account all of the regulations in play. Califf doesn’t speak for the DEA and pointed out the differences between medical marijuana and adult-use (recreational) cannabis. He also seemed to stress that it should be Congress making changes concerning cannabis and that the FDA should be in referee mode.
To Read The Rest Of This Article On Green Market Report, Click Here
